-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4491 Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III
Hematology Disease Topics & Pathways:
Adverse Events
Monday, December 9, 2024, 6:00 PM-8:00 PM

Catherine Thieblemont, MD1, Yasmin H. Karimi, MD2, Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc3, Michael Roost Clausen, MD, PhD4*, Kim Linton5*, Tycel J. Phillips, MD6, Franck Morschhauser, MD, PhD7, Martin Hutchings, MD, PhD8, Rebekah Conlon, BN9*, Saurabh Mukhopadhyay10*, Aurelie Le Maitre11*, Yu Deng, PhD10*, Mariana Sacchi, MD12*, Thomas Doerr, MSc10*, Minh Dinh, MD9*, William Palo10* and Loretta Nastoupil13*

1Department of Hematology, Assistance Publique Hôpitaux de Paris - Hopital Saint-Louis, University of Paris, Paris, France
2Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
3Department of Haematology, Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia
4Vejle Hospital, Vejle, Denmark
5The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
6City of Hope, Duarte, CA
7Centre Hospitalier Régional Universitaire de Lille, Lille, France
8Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
9AbbVie Inc, North Chicago, IL
10AbbVie Inc., North Chicago, IL
11Everest Clinical Research, Markham, ON, Canada
12Genmab, Plainsboro, NJ
13MD Anderson Cancer Center, Houston, TX

Background: Epcoritamab (epcor) is a subcutaneously administered bispecific antibody (bsAb) targeting CD3xCD20 approved for the treatment of both patients (pts) with 3L+ large B-cell lymphoma (LBCL) and 3L+ follicular lymphoma (FL) as monotherapy and is being further developed in other B-cell malignancies. Cytokine release syndrome (CRS) is the most common toxicity of bsAbs, including epcor. The diagnosis of CRS requires fever, with higher-grade events including hypotension, hypoxia, and/or organ dysfunction, which can be life-threatening. A predictive CRS model was developed for another CD3xCD20 bsAb, glofitamab (Gritti G et al. Blood Adv. 2024); however, it had suboptimal performance when applied to epcor LBCL data. This highlights the need for improved models to accurately identify pts at low risk for developing severe CRS to facilitate outpatient dosing.

Methods: EPCORE™ NHL-1 (NCT03625037) is a multicohort, single-arm, phase 2 trial; the LBCL expansion cohort enrolled 157 adult pts with relapsed or refractory CD20+ LBCL, including diffuse LBCL (DLBCL) (n=139), high-grade B-cell lymphoma (n=9), Primary mediastinal B-cell lymphoma (n=4), and FL grade (G) 3B (n=5). Pts received SC epcor with 2 step-up doses: priming (0.16 mg) and intermediate (0.8 mg), followed by 48 mg full doses in 28-d Cycles (C): QW, C1–3; Q2W, C4–9; Q4W, C≥10 until progressive disease or unacceptable toxicity. Pts received CRS prophylaxis with steroids (predominantly prednisone), acetaminophen, and diphenhydramine in C1. ORR/CR rates by IRC were 63/40% (Thieblemont et al, EHA 2024). CRS was the most reported AE (51% all G [32% G1, 16% G2, 3% G3]) and most frequently occurred after the first full dose of epcor (C1 day [D] 15).

Multiple logistic regression with 10-fold cross-validation and clinical interpretation were used to develop an epcor-specific model with risk scoring to identify factors predictive of developing G2+ CRS after the first full dose of epcor (C1D15). Potential factors included baseline characteristics (age, performance status, medical history, prior treatment, and disease burden) and laboratory data. Performance of the glofitamab 5-factor CRS model was assessed by applying the model to the epcor data in C1 and evaluating the negative predictive value (NPV) and the statistical significance of the model variables.

Results: The epcor model development included a total of 147 pts with relapsed or refractory LBCL who received the first full dose (C1D15), of which 24 (16%) pts had G2+ CRS following that dose. A 3-factor model was identified using the following characteristics: (1) prior CAR T use (Yes vs No; odds ratio [OR] 0.11; P=0.0042); (2) extranodal disease (Yes vs No; OR 3.89; P=0.0420); and (3) baseline total metabolic tumor volume (TMTV) (≥80 mL vs <80 mL; OR 2.66; P=0.0659). A risk score (range, −2.2 to 2.4) assigns pts with a score of <1 as “low risk.” Of the 70 pts assigned as low risk by the model, 68 did not have G2+ CRS after the first full dose of epcor (NPV of 97%). The recall of the model was 92%. Validation of the model with other external datasets is planned. Previous studies have reported the glofitamab 5-factor CRS model to have an NPV of 97%; however, it did not perform well for predicting G2+ CRS for the epcor LBCL cohort. The resulting NPV was 80% and all factor P-values were >0.5.

Conclusions: The epcor predictive 3-factor model uses baseline characteristics that can be calculated from local pretreatment assessments: prior CAR T, extranodal disease, and TMTV. This model was developed prior to the implementation of EPCORE NHL-1 C1 optimization measures (dexamethasone and fluids), which have further reduced the rates and severity of CRS in pts with LBCL. The model yielded an NPV of 97%, which could still be useful in identifying those already at lower risk of G2+ CRS, irrespective of the choice of steroids. The availability of TMTV may vary based on the clinical setting; however, as TMTV emerges as an important prognostic factor in LBCL, it is expected to become more readily available (Vercellino et al, Blood 2020). Once validated, adoption of this epcor-specific prediction model may support clinicians to tailor CRS monitoring, improving patient outcomes and resource utilization.

Disclosures: Thieblemont: Amgen: Consultancy, Honoraria, Other: Travel and accommodation, Speakers Bureau; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; ADC Therapeutics: Honoraria; Sanofi: Honoraria; Regeneron: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Travel and Accommodation, Speakers Bureau; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Travel and accommodation, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: Travel and accommodations, Research Funding, Speakers Bureau; AstraZeneca: Honoraria; BeiGene: Consultancy, Honoraria; Cellectis: Honoraria; Novartis: Consultancy, Honoraria, Other: Travel and accommodation, Speakers Bureau; Roche: Consultancy, Honoraria, Other: Travel and accommodation, Research Funding, Speakers Bureau; Bayer: Consultancy, Honoraria, Other: Travel and accommodation, Speakers Bureau; Janssen: Consultancy, Honoraria, Other: Travel and accommodation, Research Funding, Speakers Bureau; Kite/Gilead: Consultancy, Honoraria, Other: Travel and accommodation, Research Funding, Speakers Bureau; University of Paris: Current Employment, Ended employment in the past 24 months. Karimi: Lilly/Loxo: Research Funding; Roche/Genentech: Other: Travel Expenses, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Xencor: Research Funding; AstraZeneca: Research Funding; ADC Therapeutics: Consultancy, Honoraria. Cheah: Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; MSD: Research Funding; Lilly: Other: Travel Expenses, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Speakers Bureau; Menarini: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Dizal: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Clausen: AstraZeneca: Consultancy, Honoraria, Other: Travel Expenses; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; Incyte: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Other: Travel Expenses; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses. Linton: CellCentric: Research Funding; AstraZeneca: Research Funding; ADC Therapeutics: Research Funding; MSD: Research Funding; Viracta: Research Funding; Janssen: Research Funding; Roche: Consultancy, Research Funding; Regeneron: Research Funding; Step Pharma: Research Funding; Kite/Gilead: Consultancy, Research Funding; Nurix: Research Funding; Celgene: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; MorphoSys: Research Funding; BMS: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding, Speakers Bureau; Genmab: Consultancy, Other: Member of the Epcoritamab Global Council, Research Funding. Phillips: Lymphoma & Myeloma Connect: Honoraria; ADC Therapeutics: Consultancy; TG Therapeutics: Consultancy; Genmab: Consultancy; Celgene: Consultancy; Kite/Gilead: Consultancy; Curis: Consultancy; Gilead Sciences: Consultancy; Bayer: Consultancy, Research Funding; Genentech: Consultancy; Incyte: Consultancy; Pharmacyclics: Consultancy; AbbVie: Research Funding; Pharmacyclics/Janssen: Research Funding; Seattle Genetics: Consultancy, Honoraria. Morschhauser: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche/Genentech: Consultancy, Honoraria, Other: Payment for Expert Testimony, Honoraria for Scientific Lectures; Chugai: Honoraria; Eisai: Honoraria; Servier: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead Sciences: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Hutchings: AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen/J&J: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding. Conlon: AbbVie: Current Employment, Other: stockholder of AbbVie. Mukhopadhyay: AbbVie: Current Employment, Other: stockholder of AbbVie. Le Maitre: Everest Clinical Research: Current Employment; AbbVie: Consultancy. Deng: AbbVie: Current Employment. Sacchi: Genmab: Current Employment, Current equity holder in publicly-traded company, Other: owns Genmab stock. Doerr: AbbVie Inc.: Current Employment, Current holder of stock options in a privately-held company. Dinh: AbbVie: Current Employment. Palo: AbbVie: Current Employment, Other: stockholder of AbbVie. Nastoupil: Regeneron: Consultancy, Honoraria; Novartis: Honoraria, Research Funding; Merck: Honoraria, Research Funding; Gilead Sciences/Kite Pharma: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Genmab: Honoraria, Research Funding; Incyte Corporation: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Denovo Biopharma: Honoraria; Caribou Biosciences: Honoraria, Research Funding; BMS: Honoraria, Research Funding; ADC Therapeutics: Honoraria; AbbVie: Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Abbvie, BMS, Caribou Biosciences, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Merck, Novartis, Regeneron, Takeda: Consultancy; BMS, Caribou Biosciences, Daiichi Sankyo, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Merck, Novartis, Takeda: Research Funding; Abbvie, BMS, Caribou Biosciences, Daiichi Sankyo, Genentech, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Novartis, Takeda: Honoraria.

*signifies non-member of ASH